Document is current
Any future updates will be listed below
-
Authors
Sanabria-Salas, Maria Carolina https://orcid.org/0000-0002-7946-2026
Anggala, Nina C. https://orcid.org/0009-0000-5761-2524
Gillies, Brittany https://orcid.org/0000-0003-1389-8027
Farncombe, Kirsten M. https://orcid.org/0000-0001-9413-201X
Hofstedter, Renee https://orcid.org/0000-0002-9977-6807
Peck, Larissa https://orcid.org/0009-0006-0551-7940
Purnaghshband, Helia https://orcid.org/0000-0002-7731-1670
Redondo, Laura https://orcid.org/0009-0008-3528-6973
Thain, Emily https://orcid.org/0000-0002-8347-9998
Xu, Wei https://orcid.org/0000-0002-0257-8856
Sabatini, Peter https://orcid.org/0000-0002-3361-0468
Bedard, Philippe L. https://orcid.org/0000-0002-6771-2999
Kim, Raymond H. https://orcid.org/0000-0002-2147-8674
-
Funding
Funding for this research was provided by:
Ontario Institute for Cancer Research through funding provided by the Government of Ontario and the Princess Margaret Cancer Foundation
Bhalwani Family Charitable Foundation
Karen Green and George Fischer Genomics and Genetics Fund
Lindy Green Family Foundation
FDC Foundation (FDC Foundation)
Shar Foundation
Devine/Sucharda Charitable Foundation
Leslie E. Born
Hal Jackman Foundation
Nicol Family Foundation
Goldie R. Feldman
Princess Margaret Cancer Foundation
- License Information
-
More Information
Article History
Received: 18 October 2024
Accepted: 9 January 2025
First Online: 30 January 2025
Declarations
:
: This study was conducted in accordance with the principles of the Declaration of Helsinki and approved by the Ontario Cancer Research Ethics Board (OCREB, Approval No. 16–018). The approval covers all procedures within the Ontario-Wide Cancer Targeted Nucleic Acid Evaluation (OCTANE) Clinical Trial, including the informed consent process. This Ethics Board oversees the ethical conduct of this study at the Princess Margaret Cancer Centre.
: Not applicable.
: P.L. Bedard has institutional financial interests (sponsored clinical trials) related to Bristol-Myers Squibb, Sanofi, AstraZeneca, Genentech/Roche, GlaxoSmithKline, Novartis, Merck, Seattle Genetics, Lilly, Amgen, Bicara, Zymeworks, Medicenna, Bayer, Takeda, Gilead Sciences, and LegoChem Biosciences, and has also served on advisory boards (uncompensated) for Bristol–Myers Squibb, Sanofi, Pfizer, Genentech/Roche. All the remaining authors have no conflicts of interest to disclose.
: Was obtained from all participants at enrollment, which detailed the potential discovery of inherited DNA changes through tumor sequencing. Patients were informed of the risk associated with these findings and were given the option to receive results through their oncologist and be referred to the genetic clinic for counseling and germline confirmation.
